The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 04, 2025

Filed:

Sep. 11, 2018
Applicant:

Shanghai Public Health Clinical Center, Shanghai, CN;

Inventors:

Jianqing Xu, Shanghai, CN;

Xiaoyan Zhang, Shanghai, CN;

Xinci Xie, Shanghai, CN;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/145 (2006.01); A61K 39/275 (2006.01); A61P 31/16 (2006.01); C07K 14/005 (2006.01); C12N 7/00 (2006.01); C12N 15/86 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/145 (2013.01); A61K 39/275 (2013.01); A61P 31/16 (2018.01); C07K 14/005 (2013.01); C12N 7/00 (2013.01); C12N 15/86 (2013.01); A61K 2039/543 (2013.01); A61K 2039/545 (2013.01); C12N 2710/10043 (2013.01); C12N 2710/10343 (2013.01); C12N 2710/24134 (2013.01); C12N 2760/16122 (2013.01); C12N 2760/16134 (2013.01); C12N 2800/00 (2013.01);
Abstract

The present disclosure relates to a novel influenza immunogen with broad-spectrum anti-influenza virus effect and the immunization method thereof. The present disclosure provides a novel anti-influenza immunogen whose sequence comprises the amino acid sequence shown in SEQ ID No: 1 and SEQ ID No: 2, or an immunogenic fragment thereof, or a combination thereof. In addition, the present disclosure also provides use of the recombinant vector vaccine using said immunogen in the anti-influenza vaccine, and the immunization method of the recombinant vector vaccine using said immunogen. Through the sequential administration of multiple vector vaccines expressing the novel influenza immunogen, and the combined use of systemic administration and local administration, a high-level T cell immune response is induced in the local respiratory tract, which can produce broad-spectrum protection against multiple influenza virus infections.


Find Patent Forward Citations

Loading…